Parexel Boosts RBM Offering
Parexel, a leading provider of Clinical, Consulting and Commercial solutions announced its strategic collaboration with CluePoints, a provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software.
The addition of CluePoints’ CSM technology to facilitate the early identification of anomalous data, optimize on-site and central monitoring and reduce overall regulatory submission risk, coupled with Parexel’s extensive industry experience and RBM expertise, will help to meet the evolving needs of the industry and deliver safe and effective treatments to patients.
For further information on CluePoints' solutions, please visit www.cluepoints.com.
For further information on Parexel, please visit www.parexel.com.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025